Tavo Biotherapeutics

Biotech · Private

Novel gene therapy and small molecule therapeutics for glaucoma and retinal diseases

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · tavobio.com

Sector: Biotech
Total capital: $3.2M

Federal grants: $3.2M; 8 awards · 2019–2025; 8.0× sector median 1 award
Private capital raised: None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts: None on recordNo federal contract awards found.
Granted patents: None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

Latest events

Sep 2025Federal grantHealth and Human S · Phase II · Late-stage Pre-clinical Development and GMP Production of a First-in-Class Extended Release IOP-lowering Formulation$1M
Aug 2024Federal grantHealth and Human S · Phase II · Late-stage Pre-clinical Development and GMP Production of a First-in-Class Extended Release IOP-lowering Formulation$1.1M
Feb 2024Federal grantHealth and Human S · Phase I · Development of a novel depot delivery system for a glaucoma therapeutic$82K
Dec 2023Federal grantHealth and Human S · Phase I · Development of a novel depot delivery system for a glaucoma therapeutic$57K
Aug 2023Federal grantHealth and Human S · Phase I · Development of a novel depot delivery system for a glaucoma therapeutic$336K
May 2021Federal grantHealth and Human S · Phase I · Neuroprotective Properties of a Novel Glaucoma Drug and Formulation$357K
Jan 2020Federal grantHealth and Human S · Phase I · Extended release formulation of a new IOP lowering drug for improved treatment of glaucoma$55K

Show 1 earlier federal award

May 2019Federal grantHealth and Human S · Phase I · Extended release formulation of a new IOP lowering drug for improved treatment of glaucoma$225K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

Vor BiopharmaSimilar federal contract value in Biotech · null in contracts
Sail BiomedicinesSimilar federal contract value in Biotech · null in contracts
REMD BIOTHERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
TEAMEDON INTERNATIONAL, INC.Similar federal contract value in Biotech · null in contracts
Recourse Biologics, Inc.Similar federal contract value in Biotech · null in contracts
Lyell ImmunopharmaSimilar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.